• L-Ornithine in Liver–Brain Metabolism Research

  2026-09-23

  Use L-Ornithine to probe how urea-cycle disruption may connect hepatic metabolism with astrocyte function, rather than treating it as a generic amino-acid supplement. This workflow translates a recent realgar-toxicity study into practical metabolite, enzyme, and cell-based experiments—with clear limits on what the evidence establishes.

• TMEM16F, Ferroptosis, and Tumor Immune Rejection

  2026-09-23

  Yang et al. identify TMEM16F-mediated plasma-membrane lipid scrambling as an execution-stage suppressor of ferroptosis, extending ferroptosis biology beyond redox control. The study links defective scrambling to membrane collapse, danger-signal release, slower tumor progression, and improved response to PD-1 blockade, providing a mechanistic rationale for targeting membrane repair and remodeling.

• Berberine, RXRα/PPARγ, and SASP in Atherosclerosis

  2026-09-22

  A 2025 study identifies an RXRα/PPARγ/NEDD4 signaling axis through which berberine suppresses SASP-related inflammation in macrophage-derived foam cells and atherosclerotic plaques. By combining mouse disease modeling, foam-cell assays, Smart-seq profiling, and macrophage-specific RXRα knockdown, the work connects nuclear-receptor activity with ubiquitin-mediated regulation of the GATA4/p62 complex.

• Chronic Cabozantinib Adaptation in RCC

  2026-09-22

  This study distinguishes early and chronic signaling responses to Cabozantinib in renal cell carcinoma using quantitative phosphoproteomics. Its central finding is that prolonged exposure preserves suppression of MET activation-loop phosphorylation while selectively remodeling adhesion-, stress-, and MAPK/AP-1-associated networks linked to modest, context-dependent motility changes.

• Apicidin: Histone Deacetylase Inhibitor Workflows

  2026-09-21

  Apicidin combines a potent HDAC3-preferred biochemical profile with practical applications in chromatin, cancer, parasite, and reproductive-toxicity assays. This guide translates its mechanism into controlled dosing, meiotic imaging, acetylation analysis, and troubleshooting strategies without confusing research recommendations with validated clinical protocols.

• Septin4, VHL, and HIF-1α in Cardiac Hypoxia

  2026-09-21

  The reference study identifies HIF-1α as a previously unrecognized Septin4-interacting protein in hypoxia-exposed cardiomyocytes and shows that Septin4 promotes VHL-dependent HIF-1α degradation. This mechanism connects a mitochondrial proapoptotic factor to oxygen-sensing control and provides a mechanistic framework for interpreting hypoxia, apoptosis, and HIF stabilization experiments.

• Mifepristone (RU486) Assay Workflows

  2026-09-20

  Mifepristone (RU486) enables controlled interrogation of progesterone receptor signaling across cancer, reproductive, and cell-function models. This workflow pairs concentration-response experiments with orthogonal phenotypic and transcriptomic readouts to improve mechanistic confidence and troubleshooting.

• Cediranib: Reading VEGFR Biology in Layers

  2026-09-19

  Cediranib and AZD2171 offer a powerful way to study VEGFR signaling, but biochemical potency alone does not define cellular response. This article presents a layered assay strategy that separates pathway engagement, growth inhibition, and cell death for more rigorous cancer research.

• MK-1775: Wee1 Kinase Inhibitor Research Guide

  2026-09-18

  MK-1775 is a selective Wee1 kinase inhibitor that blocks inhibitory CDC2 phosphorylation and disrupts the G2 DNA damage checkpoint. Its strongest research rationale is combination testing with DNA-damaging agents in p53-deficient tumor models, while separate measurements of growth arrest and cell death are needed for accurate interpretation.

• Toremifene in Prostate Cancer: Linking ER and Ca2+

  2026-09-18

  Toremifene provides a receptor-level lens for prostate cancer research, while emerging evidence on the TSPAN18–STIM1–Ca2+ axis suggests a practical path from hormone signaling to metastatic mechanism.

• T0070907: A Strategic Probe of PPARγ Biology

  2026-09-17

  T0070907 is more than a potent PPARγ antagonist: it is a mechanistically informative tool for separating receptor-dependent transcription from context-specific cellular effects. This article connects PPARγ/RXRα biology, adipogenesis inhibition, cancer cell-cycle phenotypes, and the RXRα/PPARγ/NEDD4 axis described in atherosclerosis research.

• Thymoquinone: Designing Better Cardiotoxicity Assays

  2026-09-17

  Thymoquinone offers a useful framework for studying doxorubicin-associated cardiac injury beyond generic antioxidant testing. This article translates mouse findings on Nrf2/HO-1 signaling, ferroptosis, and mitochondrial preservation into a practical, multi-readout assay strategy.

• Thioredoxin System Drives CHK1 Inhibitor Sensitivity

  2026-09-16

  A 2024 Nature Communications study identifies thioredoxin 1 as a determinant of CHK1 inhibitor sensitivity in non-small cell lung cancer. Its data connect thioredoxin-dependent redox recycling of RRM1, ribonucleotide reductase activity, and deoxynucleotide availability, providing a mechanistic rationale for combining CHK1 and thioredoxin reductase inhibition.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-09-16

  A 2026 MedComm study identifies a NAT1–ENO1–lactate pathway that links tumor glycolysis to PD-L1 stabilization and immune escape in colorectal cancer. Its combination of multi-omics, biochemical experiments, patient datasets, and mouse models provides a mechanistic framework for studying how lactate metabolism may influence checkpoint-blockade responses.

• T0070907: Practical PPARγ Assay Design

  2026-09-15

  A scenario-based guide to using T0070907 (SKU A4301) as a defined PPARγ antagonist in adipogenesis, viability, and cancer cell-cycle studies. It connects biochemical potency with practical stock preparation, controls, interpretation, and vendor-selection criteria.

8721 records 1/582 page Next 12345 下5页 Last page